Changing the World with innovative technology.

About CuraLase

CuraLase clinics have administered over 100,000 treatments to over 8,000 patients from 44 states and 31 countries, establishing an international reputation for exceptional patient care. Achieving over a 90% success rate, CuraLase offers a non-invasive treatment option to individuals with pain. CuraLase delivers a pathway for patients to “get their quality of life back.”




Why CuraLase?

The CuraLase crystal controlled frequency Photon Beam Therapy technology produces a monochromatic, coherent beam, which delivers the purest, most powerful and deepest penetrating source of energy to the cells.

The results are relief of pain, decreasing inflammation, increasing circulation and accelerated healing.

The CuraLase Photon Beam Therapy delivers a unique wavelength which transports photons of energy to the deep tissue rather than being absorbed superficially. This enables the photons to reach the targeted tissue and stimulate the cellular process. The higher energy state (ATP) enables the cell to carry out it’s cellular function at an enhanced level.

CuraLase Medical Advisory Board

John Charles, MD, FACEP

The CuraLase History

Since its founding in 2005, CuraLase has been an innovator in non-invasive Photon Therapy treatment for a multitude of painful conditions. Roger Porter, inventor and engineer, was seeking an alternative treatment for a family member’s excruciating pain from rheumatoid arthritis when he met Frank G. McArthur, MD. Dr. McArthur had previously been the Medical Director of over 3,000 rehabilitation hospitals (Health South). Working together, Porter and McArthur researched and developed an innovative device and treatment protocols. In December 2005, the CuraLase device was FDA cleared as a risk free treatment for pain. The FDA rated the CL1000 with the safest classification awarded to any treatment modality. The first clinic opened in March 2006 in Myrtle Beach, South Carolina. Porter and a team of seven physicians refined the treatment protocols and developed new treatment protocols with greater than a 90% success rate.


For over a decade and a half, the developers of CuraLase have been refining this photon delivery technology, and have developed a device that provides a wavelength and delivery system that not only is matched specifically to the receptors at the cellular level, but also avoids absorption by water, fat and other soft tissue during the delivery process.
Photon Beam Therapy is the delivery of photons targeting a specific area of tissue. The effectiveness of photon therapy is proportionate to the dosage of energy delivered, the abundance of chromophores and intracellular molecular substrates that are capable of absorbing and responding to the photon stimulation in the targeted tissue.
When the photons are delivered with the appropriate parameters (wavelength and dosage) the energy is absorbed by the molecular substrates in the mitochondria. These substrates, known as chromophores, are integrated into the mitochondrial respiratory chain. The respiratory chain is subsequently stimulated to increase ATP production.
The result of the increased ATP production is tissue-specific and positive effects have been demonstrated. These include resolution of inflammation and increasing circulation which aids in wound healing and pain relief.


Changing the World with innovative technology.

CuraLase was awarded FDA clearance in 2005.


Harvard clinical trial proves PBM activates stem cells to regenerate tissue

Study Location:
Harvard School of Engineering and Applied Sciences (SEAS)
Author Information:
David J. Mooney, Praveen Arany, Ph.D., 

Harvard’s groundbreaking new research in the use of PBM to stimulate stem cells to regrow tissue is generating interest and excitement throughout the medical community.
Stem cells stimulated by PBM has “profound beneficial effects”.

Study Location:
The George S. Wise Faculty of Life Sciences, Tel-Aviv University, Tel-Aviv 69978, Israel
Author Information:
Tuby H, Maltz L, Oron U.

The application of PBM offers a novel approach to induce BM-derived MSCs, which are consequently recruited from the circulation to the infarcted heart and markedly attenuate the scarring process post-MI.
PBM to the Bone Marrow Reduces Scarring and Improves Heart Function Post-Acute Myocardial Infarction.

Study Location:
1 Cardiology Division, Assaf Harofeh Medical Center , Zerifin, Israel .
2 Sackler School of Medicine, Tel Aviv University , Tel Aviv, Israel .
3 Deprtment of Zoology, Faculty of Life Sciences, Tel-Aviv University , Tel Aviv, Israel.
4 Preclinical Unit, Assaf Harofeh Medical Center , Zerifin, Israel.
5 Department of Radiology, Assaf Harofeh Medical Center , Zerifin, Israel.
6 School of Veterinary Medicine, Hebrew University , Jerusalem, Israel.
7 Heart Institute, Kaplan Medical Center , Rehovot, Israel .
8 Cardiac MRI Unit, Shiba Medical Center , Ramat-Gan, Israel.
Author Information:
Blatt A, Elbaz-Greener GA, Tuby H, Maltz L, Siman-Tov Y, Ben-Aharon G, Copel L, Eisenberg I, Efrati S, Jonas M, Vered Z, Tal S, Goitein O, Oron U.

PBM application to BM for MI caused a significant reduction in scarring, enhanced angiogenesis and functional improvement both in the acute and long term phase post-MI.
Induction of Autologous Bone-Marrow Stem Cells by PBM Has Beneficial Effects on the Kidneys Post-Ischemia-Reperfusion Injury.

Study Location:
The George S. Wise Faculty of Life Sciences, Tel-Aviv University, Tel-Aviv, Israel.
Author Information:
Hana Tuby, Lidya Maltz, Uri Oron

Stem cells stimulated with PBM can do more than just reduce scar tissue in hearts after heart attack. Additional studies show that stem cells can rejuvenate liver and kidney, and even migrate from bone marrow to the ischemia-reperfusion injury in the kidney resulting in improved organ function. Is this proof-of-concept for an underlying mechanism by which laser therapy, used to relieve pain in the lower back, knees or joints, could be repairing bone or muscle tissue?

Contact CuraLase